Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791843 · ClinicalTrials.gov registry record · Phase 2
The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00791843: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT00791843 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00791843, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
PP1- The purpose of this study is to determine whether giving more of the hormone produced by everyone called growth hormone releasing hormone (GHRH) can improve heart function in individuals with congestive heart failure. You must be 50 years old or older, have a diagnosis of congestive heart failure, and have a high likelihood of having lower than normal growth hormone effect. GHRH is approved by the US FDA for treatment in children with growth hormone deficiency because GHRH stimulates Growth Hormone (GH). Its use for treatment of congestive heart failure in adults is investigational. Growth hormone releasing hormone is a hormone produced in the brain. We will be using synthetic hormone made in the laboratory. It is identical to the hormone in the brain. Many older people, due to aging have low levels of growth hormone. The aim of this study is to find out whether restoring growth hormone levels to the levels found in younger individuals and then maintaining those levels for 12 weeks will help strengthen heard muscles in older persons with congestive heart failure.
Interventions
- DRUG Growth hormone releasing hormone/ placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2004-03 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00791843
The ClinicalTrials.gov registry entry for NCT00791843 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Growth hormone releasing hormone/ placebo is the first listed.
NCT00791843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00791843 about?
NCT00791843 is a clinical study titled "The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure". PP1- The purpose of this study is to determine whether giving more of the hormone produced by everyone called growth hormone releasing hormone (GHRH) can improve heart function in individuals with congestive heart failure. You must be 50 years old or older, have a diagnosis of congestive heart failu...
What is the current status of trial NCT00791843?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2004-03. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00791843?
The interventions under investigation include: Growth hormone releasing hormone/ placebo (DRUG).
Who is sponsoring clinical trial NCT00791843?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.